Table 4.
Effect of 21 days treatment with 10 mg/day NOMAC on mean metabolic parameters in OVX rats compared with intact and OVX controls
| Alkaline phosphatase (U/L) | Glucose (g/L) | Insulin (ng/mL) | Triglycerides (mmol/L) | Total cholesterol (g/L) | HDL cholesterol (g/L) | |
|---|---|---|---|---|---|---|
| Intact control |
124 |
1.06 |
0.61 |
0.48 |
0.58* |
0.33 |
| OVX control |
150 |
1.04 |
0.71 |
0.49 |
0.70 |
0.38 |
| NOMAC | 156 | 1.03 | 0.72 | 0.54 | 0.72 | 0.40 |
ANOVA, analysis of variance; HDL, high-density lipoprotein; NOMAC, nomegestrol acetate; OVX, ovariectomized. N = 10 per group; * P<0.05 vs OVX control (ANOVA).
Female rats weighing 180 to 200 g were OVX or kept intact 1 week before treatment was started. Rats (n = 10) were orally treated with vehicle or 10 mg/kg/day of NOMAC for 3 weeks. Blood samples were collected from fasting animals from the retro-orbital venous sinus under light ether anesthesia 1 hour ±30 minutes after treatment. Plasma samples were stored at –20ºC until measuring the alkaline phosphatase, glucose, insulin, triglycerides, cholesterol, and HDL cholesterol.